细胞治疗:轴的光COVID-19新兴。

文章的细节

引用

复制到剪贴板

Kumar Jeyaraman M, Ranjan R, R, Arora, Chaudhary D, Ajay党卫军,耆那教的R

细胞治疗:轴的光COVID-19新兴。

干细胞Investig。2020年6月30日,7:11。doi: 10.21037 / sci - 2020 - 022。eCollection 2020。

PubMed ID

32695804 (在PubMed

]

文摘

COVID-19大流行已经面对虚弱的呼吸影响更加明显,尤其是在高危个体。潜在的系统性疾病的个体更倾向,容易受到SARS-CoV-2传染性遭受严重的后果。病理生理变化识别细胞激素风暴机制设置一系列不利的临床环境。因此,将它与高死亡率。这个权证紧急考虑等不同形式的细胞疗法。细胞治疗(CT)是一种新的医学模式在蜂窝材料管理病人的治疗目的。在这方面,间充质干细胞(msc)间质血管中成果最有前途的分数(SVF);胎盘细胞;自然杀伤(NK)细胞和血小板分别溶解产物。后CT的管理按照优先路线,这些修改微环境中发挥关键作用的肺组织与他们截然不同的机制。 Evidences have shown how their immunomodulatory action repairs and prevents lung injury which in turn improvise the compliance of lungs. In this review article we have discussed these emerging novel approaches and their target step serving as a ray of hope to combat severe form of COVID-19. Currently these aren't approved for preventing or treating COVID-19 cases, however clinical trials are afoot to dispense the utmost understanding in terms of efficacy and safety concerns.

beplay体育安全吗DrugBank数据引用了这篇文章

药物

血小板溶解产物